Immunogenicity of Biopharmaceuticals

1. Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview
Camilla Foged, Anne Sundblad

2. Clinical Aspects of Immunogenicity to Biopharmaceuticals
Simona Malucchi, Antonio Bertolotto

3. Assessment of Unwanted Immunogenicity
Meenu Wadhwa, Robin Thorpe

4. Models for Prediction of Immunogenicity
Erwin L. Roggen

5. Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars
Marco van de Weert, Eva Horn Møller

6. Case Study: Immunogenicity of rhEPO
Arno Kromminga, Gilbert Deray

7. Case Study: Immunogenicity of Interferon-Beta
Klaus Bendtzen, Arno Kromminga

8. Case Study: Immunogenicity of Insulin
Henriette Mersebach, Fannie Smith, Thomas Sparre, Lisbeth Bjerring Jensen

9. Case Study: Immunogenicity of Factor VIII
Silke Ehrenforth, Stephanie Seremetis

10. Case Study: Immunogenicity of Natalizumab
Meena Subramanyam

11. Case Study: Immunogenicity of Anti-TNF Antibodies
Klaus Bendtzen

12. Heparin-Induced Thrombocytopenia
Carmel A. Celestin, John R. Bartholomew

13. Presenting an Immunogenicity Risk Assessment to Regulatory Agencies
Paul Chamberlain

DRM-restrictions

Printing: not available
Clipboard copying: not available

Nyckelord: TECHNOLOGY & ENGINEERING / Biomedical TEC059000